Cite
HARVARD Citation
Taieb, J. et al. (n.d.). 2167 Microsatellite status predicts BRAF V600E and KRAS exon 2 mutations prognostic value in stage III colon cancers (CC) patients treated with adjuvant FOLFOX +/- cetuximab. A post-hoc analysis of the PETACC8 trial. European journal of cancer. pp. S389-. [Online].